Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
about
Alemtuzumab for multiple sclerosisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisAlemtuzumab for multiple sclerosisDimethyl fumarate for multiple sclerosisRituximab for relapsing-remitting multiple sclerosisPaediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment ChoicesThe Production Processes and Biological Effects of Intravenous ImmunoglobulinClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisAlzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentComparative efficacy and acceptability of psychotherapies for acute anxiety disorders in children and adolescents: study protocol for a network meta-analysisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysisReview of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsCladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear CellsManaging Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention.Human Adipose Stromal/Stem Cells from Obese Donors Show Reduced Efficacy in Halting Disease Progression in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosisAdrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trialCognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKOREDeterminants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.Current perspectives on interferon Beta-1b for the treatment of multiple sclerosisAzathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trialFingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisClinical trials in noninfectious uveitisA prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor CellsExamining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot studyAlemtuzumab in the treatment of multiple sclerosis.Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.Evaluating the safety of β-interferons in MS: A series of nested case-control studies.Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
P2860
Q24185899-05D85DCF-0FB5-4629-A2DB-53A223239D81Q24194800-4B48676D-D40A-482C-94FA-D6ADB7F42550Q24195076-BFD74124-CDD3-45A1-8450-B8D9FECC9592Q24197602-124E6703-081C-467E-8BF0-0EFD1F8103A0Q24201928-3DFD2F53-3F4D-4A26-B3E1-DE1ABCA1A0F3Q26748229-51D50EFC-789C-4636-987F-78F9C2198AD5Q26752540-6518976D-E79F-44AB-BE80-7EE61F610A1DQ26771635-E7186A16-2250-4261-947E-56833348FE51Q26773978-16451F76-7EB5-4F70-B3AD-A25B297DA2CEQ26776157-C7F7444F-A4B2-44F1-879F-5C3C52A02779Q26786702-F5D3A743-1559-435E-BCE4-6B1D53D842CAQ26798434-40B63559-9AFD-4FA3-8981-7BD0CA50DF56Q26828452-8C02A961-F671-4318-B2E1-68903D0D172AQ26864418-26F567A7-7CD8-4BE0-8C51-F1E10AE9EAE5Q27009769-1FAA72AD-C17A-4ACE-9AED-103100ABFBF8Q28548449-3CC810EE-29E9-4DAD-8CA8-C42AC59F0B28Q30409871-D3CF543B-760B-4ADF-A6ED-E416D2441600Q30731580-60557E64-39E1-4904-B310-4FEE0D9E02AEQ31002774-9AD13062-43A2-4934-9A15-C01B30B9C130Q33589934-2023BED3-4F43-4E84-96FC-EF80534A8BCBQ33589940-93732D77-2DE8-4F6B-868A-1293895CA39CQ33610126-10917866-1D0C-4850-A992-9B833FC86B5EQ34253488-58DEEB6D-D11F-4F2F-A77E-A825650063F0Q34526979-F2A700B7-275C-4C2C-9DD6-20571B91B03AQ34538811-B694CECD-0C69-49A8-AE5F-ACADD3C39CC7Q35651621-5C6A3C40-8C7D-46DF-A987-3A33E3249711Q35681664-7DE9F87C-5F73-425C-8DF5-405C908606BEQ35736039-0CA61B88-5A7A-47C7-A33A-F4B855EF254CQ36290946-110B52C8-2B30-4FDA-825C-74D9F447FAABQ36782920-D3CC3B38-31DF-43A3-8EDC-1130FA6810D6Q37107063-32740451-1237-4DBC-A5C4-ACBB77A44CA6Q37649028-C4E9095B-6B3E-49F1-8D9A-9285BE8D58E5Q38137114-6FA0F9D0-66AA-46EE-9DC3-38319B8CA5D9Q38608929-6743BEDA-91FA-4999-A523-5AA20C813822Q38788562-CD379179-16C5-45DC-A840-2D81B88986D3Q39020912-15A44473-3481-4229-A5CD-4E8423FBCAB7Q39093778-65F24AE0-E676-49BA-812B-E4F5E306E08FQ40710140-49C81A96-079C-49D5-A802-36CB387CB0B0Q40997871-DF992F68-2F30-4862-A0B3-D5D767C93A3FQ41721827-E7A13C28-A190-4FDB-A389-92801D0AF70E
P2860
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@ast
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en-gb
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@nl
type
label
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@ast
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en-gb
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@nl
prefLabel
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@ast
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en-gb
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@nl
P2860
P50
P921
P3181
P1476
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
@en
P2093
Laura Vacchi
P2860
P3181
P356
10.1002/14651858.CD008933.PUB2
P50
P577
2013-06-06T00:00:00Z